[{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"ae39f3e1-b6c3-41e3-9be2-0e22cc46ebd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04808791","created_at":"2021-03-22T11:52:09.750Z","updated_at":"2024-07-02T16:34:25.963Z","phase":"Phase 2","brief_title":"iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT04808791","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 07/07/2023","primary_completion_date":" 07/07/2023","study_txt":" Completion: 07/21/2023","study_completion_date":" 07/21/2023","last_update_posted":"2024-06-14"},{"id":"f7adec30-958d-4721-9a82-00722f4075ec","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03992456","created_at":"2021-01-18T19:37:42.598Z","updated_at":"2024-07-02T16:35:02.247Z","phase":"Phase 2","brief_title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","source_id_and_acronym":"NCT03992456 - PULSE","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • MET • NRAS • MSI • PTEN • CD73 • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 amplification • PIK3CA mutation • MET amplification • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-21"},{"id":"80befaa4-53a0-4489-baa2-338cc2dfb32a","acronym":"TIBET","url":"https://clinicaltrials.gov/study/NCT04489173","created_at":"2021-01-18T21:34:16.480Z","updated_at":"2024-07-02T16:35:03.947Z","phase":"Phase 2","brief_title":"TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT04489173 - TIBET","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 01/08/2024","primary_completion_date":" 01/08/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-14"},{"id":"00d242f0-fa63-4201-9e35-6a3b26211f88","acronym":"","url":"https://clinicaltrials.gov/study/NCT06379399","created_at":"2024-04-23T18:55:21.127Z","updated_at":"2024-07-02T16:35:08.038Z","phase":"Phase 1/2","brief_title":"Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC","source_id_and_acronym":"NCT06379399","lead_sponsor":"Wangxia LV","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-23"},{"id":"c059badf-8a2b-4247-bace-32ba3408645c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317119","created_at":"2021-01-18T16:22:52.836Z","updated_at":"2024-07-02T16:35:11.068Z","phase":"Phase 1","brief_title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03317119","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation","tags":["BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/11/2018","start_date":" 04/11/2018","primary_txt":" Primary completion: 07/14/2023","primary_completion_date":" 07/14/2023","study_txt":" Completion: 07/14/2023","study_completion_date":" 07/14/2023","last_update_posted":"2024-04-08"},{"id":"470b1556-c556-4764-aec0-fd65bb7bee1e","acronym":"NOTABLE-308","url":"https://clinicaltrials.gov/study/NCT06343116","created_at":"2024-04-02T17:41:44.202Z","updated_at":"2024-07-02T16:35:11.906Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06343116 - NOTABLE-308","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-04-02"},{"id":"99425b86-d7f5-4e13-abcd-98632d9960ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660760","created_at":"2021-01-19T20:42:30.744Z","updated_at":"2024-07-02T16:35:12.122Z","phase":"Phase 2","brief_title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT04660760","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • lexatumumab (ETR2-ST01)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-01"},{"id":"d01d0098-4a6a-4882-a7cc-d6d702df5d85","acronym":"LONGBOARD","url":"https://clinicaltrials.gov/study/NCT04166604","created_at":"2021-01-18T20:19:53.169Z","updated_at":"2024-07-02T16:35:15.429Z","phase":"Phase 2","brief_title":"LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy","source_id_and_acronym":"NCT04166604 - LONGBOARD","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type • RAS wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-03-11"},{"id":"ad15ac21-12e0-4c36-9b7b-f02aadf94665","acronym":"SOREGATT","url":"https://clinicaltrials.gov/study/NCT04450836","created_at":"2021-01-18T21:24:46.331Z","updated_at":"2024-07-02T16:35:16.877Z","phase":"Phase 2","brief_title":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04450836 - SOREGATT","lead_sponsor":"UNICANCER","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 11/23/2024","primary_completion_date":" 11/23/2024","study_txt":" Completion: 05/23/2028","study_completion_date":" 05/23/2028","last_update_posted":"2024-03-01"},{"id":"043223c9-1b07-4370-8cca-13212df5199c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007132","created_at":"2021-08-16T16:54:41.427Z","updated_at":"2024-07-02T16:35:19.202Z","phase":"Phase 2","brief_title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05007132","lead_sponsor":"Dominik Paul Modest","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2024-02-15"},{"id":"afd94abb-f061-48a2-9c31-e7ad925496ed","acronym":"TASKIN","url":"https://clinicaltrials.gov/study/NCT05201352","created_at":"2022-01-21T13:53:29.042Z","updated_at":"2024-07-02T16:35:19.490Z","phase":"Phase 1/2","brief_title":"Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine","source_id_and_acronym":"NCT05201352 - TASKIN","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" BRAF • MSI","pipe":"","alterations":" ","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Natrunix (vilamakitug)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 10/13/2026","primary_completion_date":" 10/13/2026","study_txt":" Completion: 10/13/2026","study_completion_date":" 10/13/2026","last_update_posted":"2024-02-14"},{"id":"aa2aa9dd-953c-4710-8346-b00e3dcdc8c6","acronym":"VELO","url":"https://clinicaltrials.gov/study/NCT05468892","created_at":"2022-07-21T11:55:12.137Z","updated_at":"2024-07-02T16:35:21.371Z","phase":"Phase 2","brief_title":"Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial","source_id_and_acronym":"NCT05468892 - VELO","lead_sponsor":"University of Campania \"Luigi Vanvitelli\"","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/29/2019","start_date":" 10/29/2019","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2024-02-01"},{"id":"8237d61d-1343-4a03-a43c-b9bbdb6f38a3","acronym":"TACT-D","url":"https://clinicaltrials.gov/study/NCT03844620","created_at":"2022-06-29T09:02:08.721Z","updated_at":"2024-07-02T16:35:22.996Z","phase":"Phase 2","brief_title":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03844620 - TACT-D","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-01-18"},{"id":"ae111ff7-f7d6-4e6d-a965-a9f85b43ebd3","acronym":"ACCRU-GI-1618","url":"https://clinicaltrials.gov/study/NCT03981614","created_at":"2021-01-18T19:35:03.037Z","updated_at":"2024-07-02T16:35:23.825Z","phase":"Phase 2","brief_title":"Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer","source_id_and_acronym":"NCT03981614 - ACCRU-GI-1618","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 10/29/2019","start_date":" 10/29/2019","primary_txt":" Primary completion: 08/23/2021","primary_completion_date":" 08/23/2021","study_txt":" Completion: 04/03/2024","study_completion_date":" 04/03/2024","last_update_posted":"2024-01-10"},{"id":"750601ca-82f8-4edc-afde-2d3614d131cf","acronym":"Live-RF","url":"https://clinicaltrials.gov/study/NCT05991102","created_at":"2023-08-14T14:10:34.860Z","updated_at":"2024-07-02T16:35:25.550Z","phase":"","brief_title":"Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05991102 - Live-RF","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2023-12-21"},{"id":"01d93d84-ceb8-4d89-9e96-016cb7325fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05481463","created_at":"2022-08-01T15:55:26.976Z","updated_at":"2024-07-02T16:35:29.397Z","phase":"Phase 2","brief_title":"Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05481463","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil) • Sulanda (surufatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-11-13"},{"id":"5da3143e-2e36-47bf-ac05-b5e97e205015","acronym":"LOGICAN","url":"https://clinicaltrials.gov/study/NCT05476796","created_at":"2022-07-27T13:54:41.357Z","updated_at":"2024-07-02T16:35:33.413Z","phase":"Phase 2","brief_title":"Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05476796 - LOGICAN","lead_sponsor":"UNICANCER","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Lonsurf (trifluridine/tipiracil) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 06/23/2023","start_date":" 06/23/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-10-16"},{"id":"5b38253f-bfcb-468a-a302-a0f7d2c95576","acronym":"ACCRU-GI-2003","url":"https://clinicaltrials.gov/study/NCT05356897","created_at":"2022-05-02T11:56:49.270Z","updated_at":"2024-07-02T16:35:33.591Z","phase":"Phase 2","brief_title":"Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","source_id_and_acronym":"NCT05356897 - ACCRU-GI-2003","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2 • KRAS • BRAF • PIK3CA • NRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • HER-2 amplification • PIK3CA mutation • BRAF V600","tags":["HER-2 • KRAS • BRAF • PIK3CA • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • HER-2 amplification • PIK3CA mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tukysa (tucatinib) • Lonsurf (trifluridine/tipiracil) • Trazimera (trastuzumab-qyyp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2023-10-13"},{"id":"05075952-55a7-42e5-98df-eb7f2ac450fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031376","created_at":"2023-09-11T16:10:31.705Z","updated_at":"2024-07-02T16:35:37.518Z","phase":"","brief_title":"Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC","source_id_and_acronym":"NCT06031376","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-09-11"},{"id":"208c1d8e-ad83-4803-8b5c-193b9a7eb2cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993702","created_at":"2023-08-15T19:10:28.743Z","updated_at":"2024-07-02T16:35:39.976Z","phase":"","brief_title":"TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer","source_id_and_acronym":"NCT05993702","lead_sponsor":"China Medical University, China","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-15"},{"id":"f62074f7-72f5-40d9-9af6-475d6423cc79","acronym":"","url":"https://clinicaltrials.gov/study/NCT05927857","created_at":"2023-07-03T16:10:24.736Z","updated_at":"2024-07-02T16:35:44.283Z","phase":"Phase 1/2","brief_title":"Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .","source_id_and_acronym":"NCT05927857","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-06-30"},{"id":"b0e97c3c-c4fd-4a7e-8e46-0809254f5060","acronym":"","url":"https://clinicaltrials.gov/study/NCT05869097","created_at":"2023-05-22T16:05:41.153Z","updated_at":"2024-07-02T16:35:47.525Z","phase":"","brief_title":"Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05869097","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 04/30/2023","study_completion_date":" 04/30/2023","last_update_posted":"2023-05-22"},{"id":"02416dfe-243c-473a-8125-54370e5c5aab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274882","created_at":"2022-06-29T09:01:49.057Z","updated_at":"2024-07-02T16:35:48.318Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies","source_id_and_acronym":"NCT03274882","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 12/31/2017","primary_completion_date":" 12/31/2017","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2023-05-11"}]